The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead

News provided by

Nov 13, 2014, 09:30 ET

CHICAGO, Nov. 13, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dendreon (Nasdaq:DNDN-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report), AbbVie (NYSE:ABBV-Free Report) and Gilead (Nasdaq:GILD-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

With third quarter earnings season drawing to a close, the annual meeting of the American Association for the Study of Liver Diseases or the Liver Meeting was a key focus area last week with several companies presenting data on their hepatitis C virus (HCV) treatments at the meeting.

Meanwhile, Dendreon (Nasdaq:DNDN-Free Report) has filed for bankruptcy and Amgen (Nasdaq:AMGN-Free Report) and Regeneron (Nasdaq:REGN-Free Report) continue to impress with data on pipeline candidates.

Recap of the Week's Most Important Stories

1. With its HCV combination treatment approaching FDA approval, potentially by year end, AbbVie (NYSE:ABBV-Free Report) continues to present positive data on the cocktail treatment. At the recently held Liver Meeting, AbbVie presented data showing that the cocktail therapy treated 97.1% of liver transplant patients who had recurrent chronic GT1 HCV infection and were new to treatment after transplantation.

Meanwhile, sustained virologic response rate at 12 weeks post-treatment (SVR12) was 93.5% and 90.6% at 24 weeks in HCV patients co-infected with HIV. Moreover, there was data from another study conducted in genotype 4 patients who were new to therapy or who had failed previous treatment with pegylated interferon and ribavirin – all patients in the study achieved SVR12.

AbbVie's treatment, once approved, will enter the highly lucrative HCV market that is currently dominated by Gilead's (Nasdaq:GILD-Free Report) Sovaldi which has raked in multi-billion dollar sales for the company. Gilead's HCV product portfolio now includes Harvoni (a once-daily single tablet regimen comprising ledipasvir and Sovaldi) as well. Gilead also had a strong presence at the Liver Meeting where it presented positive data on both Sovaldi and Harvoni.

2. Regeneron and partner Sanofi are moving their experimental asthma treatment, dupilumab, into late-stage development based on encouraging positive interim data from a mid-stage study. The three highest doses of the experimental drug that were evaluated in the study met the primary endpoint. Moreover, two doses were found to be effective in a subset of patients as well as in the overall study population.

3. The FDA has set a target date for Amgen's PCSK9 inhibitor – evolocumab. Amgen, which is looking to get evolocumab approved for the treatment of high cholesterol, will receive a response on evolocumab's approval status by Aug 27, 2015. Amgen had another set of promising news on the pipeline front with experimental psoriasis treatment, brodalumab, faring better than Johnson & Johnson's Stelara in a pivotal head-to-head study. Brodalumab is one of the most interesting candidates in Amgen and partner, AstraZeneca's pipeline – earlier this year, AstraZeneca had announced that analyst estimates for non-risk adjusted peak year sales potential of brodalumab are in the range of $0.5 billion - $1.5 billion.

4. In a not so surprising move, Dendreon has filed for bankruptcy. The company has been struggling for quite some time with the performance of its sole product, Provenge, never really meeting expectations. The company tried several options earlier including streamlining of operations and layoffs. However, the company's debt levels remain high (Read more: Dendreon Shares Plummet After It Files for Bankruptcy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on DNDN - FREE
Get the full Report on AMGN - FREE
Get the full Report on REGN - FREE
Get the full Report on ABBV - FREE
Get the full Report on GILD - FREE

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.